Custom-Edited DNA: Legal Limits on the Patentability of CRISPR-Cas9's Therapeutic Applications

Noah C. Chauvin

Follow this and additional works at: https://scholarship.law.wm.edu/wmlr
Part of the Intellectual Property Law Commons, and the Science and Technology Law Commons

Repository Citation
Noah C. Chauvin, Custom-Edited DNA: Legal Limits on the Patentability of CRISPR-Cas9's Therapeutic Applications, 60 Wm. & Mary L. Rev. 297 (2018), https://scholarship.law.wm.edu/wmlr/vol60/iss1/7

Copyright © 2018 by the authors. This article is brought to you by the William & Mary Law School Scholarship Repository.
https://scholarship.law.wm.edu/wmlr
TABLE OF CONTENTS

INTRODUCTION ....................................... 299
I. SCIENTIFIC BACKGROUND ............................. 303
   A. What is CRISPR-Cas9? ............................ 304
   B. Therapeutic Applications .......................... 308
      1. Viral Infections ................................. 308
      2. Bacterial Infections ............................. 310
      3. Editing Somatic Cells ........................... 311
      4. Editing Germline Cells .......................... 312
II. LEGAL LANDSCAPE .................................. 313
   A. General Requirements for Patentability ......... 313
   B. The America Invents Act Regime ................. 315
   C. The Law as Applied to Human Biology ............ 316
      1. Fetuses ....................................... 316
      2. DNA ......................................... 317
      3. Stem Cells ..................................... 319
   D. Scholarly Perspectives on the Patentability of
      CRISPR-Cas9 ................................... 320
III. ARE CRISPR-CAS9 THERAPIES PATENTABLE? ........... 321
   A. Where Patent Protection Will Apply ............. 322
      1. Treating Viral Infections ........................ 322
      2. Treating Bacterial Infections ................... 325
   B. Where Patent Protection Will Not Apply ........... 325
      1. Editing Somatic Cells ........................... 326
      2. Editing Germline Cells .......................... 327
IV. COUNTERARGUMENTS ............................... 329
   A. CRISPR-Cas9 Should Not Be Patentable at All ...... 329
   B. Patents Have Issued on Some CRISPR-Based
      Therapies ........................................ 330
C. Some Somatic Cell Editing Should Be Patentable ........................................ 331
CONCLUSION ........................................................................... 331
Imagine a future where large corporations use CRISPR, a genetic editing tool, to modify almost every living thing. Perfectly manicured lawns are comprised of genetically-modified grasses, people adore their genetically-modified pets, and parents select only the best traits to be carried by their genetically-modified children. This is a future T. Coraghessan Boyle recently imagined in a short story in *The New Yorker*. In Boyle’s story, genetic editing is supposed to lead to perfect happiness by removing all flaws from the natural world. The only catch is that the new, genetically perfect world feels wholly unnatural to some of the people living in it.

The dystopian future envisioned in Boyle’s story is fast becoming scientifically possible. (Whether it is ethically desirable is an entirely separate matter.) CRISPR-Cas9, short for “Clustered Regularly Interspaced Short Palindromic Repeats” and “CRISPR-associated protein 9” is a genetic-editing technology that allows

---

2. Id.
3. Id.
4. Id. Boyle’s description of how genetic editing could change reproduction is illustrative: What sort of child—that was the question. Previous generations had only to fret over whether the expectant mother would bear a boy or a girl or if the child would inherit Aunt Bethany’s nose or Uncle Yuri’s unibrow, but that wasn’t the case anymore, not since CRISPR gene-editing technology had hit the ground running twenty years back. Now not only could you choose the sex of the child at conception; you could choose its other features, too, as if having a child were like going to the car dealership and picking which options to add onto the basic model. The sole function of sex these days was recreational; babies were conceived in the laboratory.
5. Id.
scientists to edit DNA with a remarkable degree of accuracy.8 It is an advance on other genetic-editing technologies, which had limited programmability and, in turn, often caused off-target effects (edits to segments of DNA that the researcher was not trying to impact).9 Scientists continuously find new, creative uses of CRISPR-Cas9,10 and the technology is increasingly in the public eye.11 The FDA recently issued a press release warning consumers that the sale of “do it yourself” CRISPR kits is against the law due to safety concerns about CRISPR-Cas9-mediated gene therapies.12 Chinese scientists reported in October of 2016 that they had injected a lung cancer patient with cells modified by CRISPR-Cas9,13 scientists at Oregon Health & Science University reported in August of 2017 that they had made CRISPR-mediated repairs to non-viable human

8. See Taeyoung Koo & Jin-Soo Kim, Therapeutic Applications of CRISPR RNA-Guided Genome Editing, 16 BRIEFINGS FUNCTIONAL GENOMICS 38, 38, 43 (2017).
embryos, and human trials of a CRISPR-based treatment for a blood disorder will begin in Europe in 2018.

Most of the legal scholarship on CRISPR-Cas9 has focused on the patent dispute between the University of California and The Broad Institute, on how the use of CRISPR should be regulated, or on the ethical concerns about how CRISPR should be used. Legal scholarship has not yet addressed the question that this Note seeks to answer: are therapeutic applications of CRISPR-Cas9 patentable? Previous articles have examined the patentability of the processes required to make CRISPR-Cas9 and transcribe it into other organisms, but have not examined the patentability of

---


17. See Evita V. Grant, FDA Regulation of Clinical Applications of CRISPR-CAS Gene Editing Technology, 71 FOOD & DRUG L.J. 608, 609 (2016); Sarah Ashley Barnett, Comment, Regulating Human Germline Modification in Light of CRISPR, 51 U. RICH. L. REV. 553, 555 (2017); Teddy Ellison, Note, Why Genetics is CRISPR Than It Used to Be: Helping the Novice Understand Germ Line Modification and its Serious Implications, 26 S. CAL. INTERDLS. L.J. 595, 596 (2017); Adam J. Gross, Comment, Dr. Frankenstein, Or: How I Learned to Stop Worrying and Love CRISPR-Cas9, 56 JURIMETRICS J. 413, 414 (2016).

CRISPR-Cas9 systems in the context of providing medical care by editing viral, bacterial, or human DNA.19

It is not clear that these CRISPR-Cas9 applications would qualify as patentable subject matter under the traditional tests for patentability.20 This issue is further complicated because federal law prevents patents from issuing “on a claim directed to or encompassing a human organism,” and it is not obvious whether CRISPR-Cas9 systems cross that line.21 The legislative history of the Act suggests that Congress designed this provision to prevent “human embryos and fetuses” from being patented.22 However, the law’s authors did intend that “genes, stem[] cells, [and] animals with human genes” would remain patentable.23 This suggests that researchers seeking to create scalable CRISPR-Cas9 treatments for a broad range of human ailments will have to do more than simply convince the FDA that their therapy is safe24: they will also likely have to litigate the question of whether their treatment is patentable subject matter under current federal law.

This Note seeks to answer that question, and concludes that while antibacterial and antiviral CRISPR-Cas9 treatments are patentable, treatments that edit somatic or germline cells are not. Part I will provide biological context, explaining what CRISPR-Cas9 is, how it

19. See supra notes 16-18 and accompanying text. This Note focuses on CRISPR-Cas9’s potential as a treatment for human illness. CRISPR-Cas9 can also be used to detect illnesses. See Janice S. Chen et al., CRISPR-Cas12a Target Binding Unleashes Indiscriminate Single-Stranded DNase Activity, SCIENCE (Feb. 15, 2018), http://science.sciencemag.org/content/early/2018/02/14/science.aar6245.full.pdf [https://perma.cc/YMC8-HUQR] (describing a CRISPR-Cas9 variant that “enables rapid and specific detection of human papillomavirus”); Jonathan S. Gootenberg et al., Multiplexed and Portable Nucleic Acid Detection Platform With Cas13, Cas12a, and Csm6, SCIENCE (Feb. 15, 2018), http://science.sciencemag.org/content/sci/early/2018/02/14/science.aaq0179.full.pdf [https://perma.cc/4JKK-RUK6] (describing CRISPR-Cas9 variants that “can detect Dengue or Zika virus”).

20. See infra Part II.A.


22. See MANUAL OF PATENT EXAMINING PROCEDURE § 2105 (9th ed. 2015), which noted that the legislative history provides some clarity as to the meaning of the AIA. The Manual quotes a statement that observes that “[t]he U.S. Patent Office has already issued patents on genes, stems cells, animals with human genes, and a host of non-biologic products used by humans, but it has not issued patents on claims directed to human organisms, including human embryos and fetuses.” Id. (quoting 157 CONG. REC. E1177-04 (2011) (statement of Rep. Weldon)).

23. Id.

differs from other genetic editing technologies, and how it may be used as a treatment for human illness in the future. Part II will provide legal context, explaining the current legal landscape for patents based on human biology. Part II will also provide a background on U.S. patent law, describe the patentability of embryos, DNA, and stem cells, and summarize some of the scholarship on the patentability of CRISPR-Cas9.

Part III will attempt some line-drawing. Are CRISPR-based treatments patentable? Are they too directed at a human organism to be patented? Does the answer change depending on the therapeutic use the DNA is put to? Part III will conclude that CRISPR-Cas9 systems used to treat viral or bacterial infections are patentable because they are analogous to non-biologic drugs, but CRISPR-Cas9 systems used to alter genetic mutations or for germline therapies are not patentable because they are directed at a human organism. Part IV considers and rejects some counterarguments to the normative framework outlined in Part III.

I. SCIENTIFIC BACKGROUND

In order to be patentable, an invention must be, among other things, a “new and useful,”25 “novel [ ],”26 and “non-obvious”27 thing or process.28 To determine whether an invention meets these requirements, a patent examiner looks at the “prior art”29—the scientific background that undergirds the patent application.30 Because the scientific background is useful not just for determining whether CRISPR-Cas9 is patentable, but also for defining precisely what it is, this Part will provide a basic introduction to CRISPR-Cas9 and its therapeutic applications.

26. Id. § 102.
27. Id. § 103.
28. Id. § 101.
29. See, e.g., id. § 102.
30. In patent law, the prior art is “[k]nowledge that is publicly ... available on the date of invention[,] to a person of ordinary skill” in that field. Prior Art, BLACK’S LAW DICTIONARY (9th ed. 2009).
A. What is CRISPR-Cas9?

Scientists have been using genome-editing technologies since 1994. The three genome-editing technologies primarily in use today are zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and CRISPR-Cas9. Of these three, CRISPR-Cas9 has the greatest therapeutic potential because it is the most scalable—when compared to ZFNs and TALENs, CRISPR-Cas9 systems are cheap, easy to produce, efficient, and can easily be tailored to edit multiple genes at a single time.

CRISPR are short sequences of DNA that code for a guide RNA (gRNA) that is then paired with a CRISPR-associated (Cas) protein, an enzyme that acts like a pair of molecular scissors and cleaves.

---

31. See Philippe Rouet et al., Introduction of Double-Strand Breaks into the Genome of Mouse Cells by Expression of a Rare-Cutting Endonuclease, 14 MOLECULAR & CELLULAR BIOLOGY 8096, 8096 (1994).


33. Thomas Gaj et al., Genome-Editing Technologies: Principles and Applications, COLD SPRING HARBOR PERSP. BIOLOGY 1, 1 (2016), http://cshperspectives.cshlp.org/content/8/12/a023754.full [https://perma.cc/4NQB-9SSZ]. While scientists have been using genome-editing technologies for decades, these three represent a significant advance over prior technology because they can target specific sites on DNA. Id. at 7. “Before the emergence of [these technologies], genetically modifying mammalian cell lines was labor intensive, costly, and often times limited to laboratories with specialized expertise. However, with the advent of cost-effective and user-friendly gene-editing technologies, custom cell lines carrying nearly any genomic modification can now be generated ... simply.” Id.


35. An enzyme is a protein produced by a cell to facilitate a chemical reaction (in this case, breaking the bonds that hold the DNA molecule together). Enzyme, BIOLOGY ONLINE DICTIONARY, https://www.biology-online.org/dictionary/Enzyme [https://perma.cc/A5ZD-MLXP].

target DNA at very specific locations in the genome.\textsuperscript{37} The gRNA steers the Cas to the appropriate cutting site on the target DNA.\textsuperscript{38}

CRISPR-Cas9 originally evolved as an immune response in bacteria; it protected the bacteria from viral infection.\textsuperscript{39} The bacteria would incorporate short sequences of DNA from viruses that had infected them into their own genetic code.\textsuperscript{40} The bacteria could then use the incorporated viral DNA to create an “immune memory” that helped it recognize an infection from the same virus in the future.\textsuperscript{41} The incorporated viral DNA would be used as a model for a gRNA.\textsuperscript{42} That gRNA could then guide a Cas9 to the virus, in order to destroy it.\textsuperscript{43} The gRNA would direct the Cas9 to the target site on the virus’s DNA, where the Cas9 would create a double-strand break in the viral DNA, destroying it and ending the infection.\textsuperscript{44}

CRISPR-Cas9 was first discovered in 2000 by researchers in Spain,\textsuperscript{45} but its genetic editing potential was not publicly recognized until 2012, when scientists at the University of California, Berkeley published a paper in the journal \textit{Science} detailing the first complete catalogue of the CRISPR-Cas9 system as found in bacteria.\textsuperscript{46}
CRISPR-Cas9 is incredibly useful as a genetic editing tool because it is highly accurate. Because the CRISPR-Cas9 gRNA is twenty nucleotides long, and each nucleotide will pair exactly with a nucleotide on the target DNA, there is less than a one in one trillion chance that the Cas9 will cleave the DNA at the wrong site. Cleaving DNA at only the intended target site is critical because any off-target editing risks damaging functioning DNA and creating serious, potentially lethal side-effects.

CRISPR-Cas9’s enormous therapeutic potential does not derive merely from the fact that it can damage DNA at very specific places. This capacity by itself is not unique, or even necessarily very helpful. After all, what frequently makes carcinogens

47. See, e.g., Yeadon, supra note 34.
48. Koo & Kim, supra note 8, at 38.
49. DNA is comprised of four nucleotides: adenine, cytosine, guanine, and thymine. Nucleotides and Bases, GENETICS GENERATION, http://knowgenetics.org/nucleotides-and-bases/ [https://perma.cc/92NY-BN8N]. Each nucleotide pairs with exactly one other nucleotide. Id. Thus there is a one in four chance that a single nucleotide of the gRNA will match with a nucleotide of the target DNA. See id. Since \((1/4)^{20} = 1/1,099,511,600,000\), there is a less than one in one trillion chance that the target DNA would contain two twenty-nucleotide sequences that are exactly the same. Of course, this assumes that DNA nucleotides are arranged randomly. In fact, scientists have found that many nucleotide sequences are repeated throughout the genome, and that these repeated sequences can serve important functions. E.g., James A. Shapiro & Richard von Sternberg, Why Repetitive DNA is Essential to Genome Function, 80 BIOLOGICAL REVIEWS 227, 243 (2005). Indeed, CRISPR’s name itself reveals that nucleotide sequences are not randomly distributed: remember that CRISPR is an acronym for “clustered regularly interspaced short palindromic repeats.” Koo & Kim, supra note 8, at 38.

50. In the genetics context, off-target editing occurs when a genetic editing technology “produce[s] unwanted DNA mutations at sites other than the desired target.” Sue McGreevey, Off-Target Gene Editing, HARV. MED. SCH. (June 25, 2013), https://hms.harvard.edu/news/genetics/target-gene-editing-6-25-13 [https://perma.cc/RAP4-U9KE].
51. See Koo & Kim, supra note 8, at 39, 43. Compare Kellie A. Schaefer et al., Unexpected Mutations After CRISPR-Cas9 Editing in vivo, 14 NATURE METHODS 547, 547-48 (2017) (reporting a study that purportedly showed thousands of off-target genetic mutations allegedly caused by CRISPR-Cas9 in mice treated with the technology), with Vivek Iyer et al., No Unexpected CRISPR-Cas9 Off-Target Activity Revealed by Trio Sequencing of Gene-Edited Mice 5 (Feb. 9, 2018) (unpublished manuscript) (available at https://www.biorxiv.org/content/early/2018/02/09/263129.full.pdf+html) [https://perma.cc/4FW4-9QEJ] (concluding that any off-target mutations in mice treated by CRISPR-Cas9 are not statistically significant from the background level of mutation found in mice untreated by CRISPR-Cas9).
52. See Koo & Kim, supra note 8, at 39-42. This is not to say that this aspect of CRISPR-Cas9 is not useful. The mere destruction of DNA can be very useful as a treatment for viral and bacterial infections. See id.; infra Parts I.B.1, I.B.2.
53. See Yeadon, supra note 34.
Carcinogenic is their ability to damage DNA.\textsuperscript{54} CRISPR-Cas9 has enormous therapeutic potential because its highly specific cutting ability targets extremely specific sequences of DNA, and can be paired with processes that insert desirable DNA at the target site, creating the potential to replace a defective gene with a functioning one.\textsuperscript{55} This means that CRISPR-Cas9 could serve as a cure to not just infectious diseases, but also inherited ones.\textsuperscript{56}

Recent research by scientists at Stanford University indicates that CRISPR-Cas9 in its current iteration may have limited effectiveness in treating human disease.\textsuperscript{57} The researchers discovered that because Cas9 (the cutting protein) is present in bacteria that frequently infect humans, we may have developed an immune response to it.\textsuperscript{58} However, the scientists concede that while their study is an important reminder to be cautious with CRISPR-Cas9, it is “not a deal-breaker, even for people with immunity to [Cas9], because there are other [cutting] proteins that could be adapted to do the job.”\textsuperscript{59} The researchers also cautioned that their results only implicate therapeutic applications of CRISPR-Cas9 where the Cas9 protein may come in contact with the human immune system.\textsuperscript{60} Indeed, “[s]ome of the first human experiments in the U.S. ... will use the Cas9 proteins on blood cells outside the body, so there’s little chance the immune system will cause any trouble.”\textsuperscript{61} In the meantime, researchers can work to determine the most effective means of deploying CRISPR-Cas9 as a therapy.\textsuperscript{62}

\begin{flushleft}
\textsuperscript{55} See Yeadon, supra note 34.
\textsuperscript{56} See Koo & Kim, supra note 8, at 40.
\textsuperscript{57} See Carsten T. Charlesworth et al., Identification of Pre-Existing Adaptive Immunity to Cas9 Proteins in Humans 2-3 (Jan. 5, 2018) (unpublished manuscript) (available at https://www.biorxiv.org/content/biorxiv/early/2018/01/05/243345) [https://perma.cc/MLJ3-VZ6A].
\textsuperscript{58} Id. at 5-6.
\textsuperscript{60} Id.; see also Charlesworth et al., supra note 57, at 7 (“Pre-existing adaptive immune responses may be of less concern for \textit{ex vivo} therapies that involve the use of Cas9 to edit cells outside of direct contact with the human immune system.”).
\textsuperscript{61} Flam, supra note 59 (emphasis added).
\textsuperscript{62} See id.
\end{flushleft}
B. Therapeutic Applications

CRISPR-Cas9 could be used to treat human illness and disease in four basic ways: it has potential to (1) combat viral infections, (2) fight bacterial infections, (3) edit somatic (non-germline) cells, and (4) edit germline cells. Each therapeutic application could be immensely important. Using CRISPR to treat viral infections could mean a cure to HIV/AIDS. Using it to treat bacterial infections could mean a solution to antibiotic-resistant tuberculosis. Editing somatic cells using CRISPR could mean an end to muscular dystrophy, or a cure for cancer. Editing germline cells could mean an end to infertility and a preemptive cure for all inheritable genetic diseases.

1. Viral Infections

Using CRISPR-Cas9 to treat viral infections such as HIV is “one of the promising new approaches in gene therapy.” Researchers have used CRISPR-Cas9 to treat a variety of viruses, including HIV, HPV, herpes, and hepatitis B. Treatment works in one of two ways: “Cas9 can target [either] viral genes or host genes that encode essential receptors to suppress infection [by] viruses.” Human clinical trials using ZFNs, another genome-editing treatment, have proved effective at treating HIV. Laboratory trials using CRISPR-
Cas9 to treat viruses have also been effective, but in some trials in which researchers targeted only one HIV gene, the virus managed to evolve into a CRISPR-Cas9-resistant mutant. 74 Researchers have suggested that the most effective CRISPR-Cas9 treatments for viral infections will target multiple genes to ensure complete removal of the virus. 75

CRISPR-Cas9 has already been used to cure HIV (although not in humans). 76 The scientists in that study used three different populations of HIV-infected lab mice, “including a ‘humanized’ [population] where human immune cells infected with the virus were transplanted in lab mice.” 77 The CRISPR-Cas9 treatment proved effective in all three populations; the treatment removed the HIV DNA from all of the mice. 78 Buoyed by their success, the researchers hope to transition next to trials in primates, with the ultimate goal of beginning human trials by 2020. 79

Scientists at Temple University have already demonstrated that CRISPR-Cas9 can also be used to effectively cure HIV in human cells. 80 They used CRISPR-Cas9 to remove the entire HIV gene from infected human immune cells in laboratory conditions. 81 It is important to note that these were not clinical trials; the tests were conducted on cell cultures (groups of cells grown outside the body) in a lab. 82 Nonetheless, the tests are an important step forward in using CRISPR-Cas9 to treat HIV.

74. Id. at 40.
75. Id.
77. Id.
78. Id.
80. Rafal Kaminski et al., Elimination of HIV-1 Genomes from Human T-lymphoid Cells by CRISPR/Cas9 Gene Editing, 6 SCI. REP. 1, 10 (2016).
81. Id. at 2.
82. Id.
2. Bacterial Infections

CRISPR-Cas9 could be used to treat bacterial infections by “target[ing] bacterial genes and thereby inhibit[ing] bacterial growth.”83 This is a particularly potent therapy when deployed against antibiotic-resistant bacteria, which cannot be effectively treated using standard medicines.84 DNA encoding the CRISPR-Cas9 treatment is delivered to the bacteria through a specially engineered virus.85 This style of treatment is especially advantageous because the CRISPR-Cas9 system is designed to target only bacterial genes.86 Therefore, there is reduced risk that the Cas9 will damage human DNA, which does not contain the bacterial DNA sequence.87

Researchers at Harvard University have already demonstrated that CRISPR-Cas9 can be used to kill antibiotic-resistant tuberculosis in laboratory conditions.88 The scientists initially wanted to pair the Cas9 already present in tuberculosis cells with a custom gRNA to initiate gene knockdowns that would kill the bacteria.89 However, they discovered that this was not an efficient treatment.90 Instead, they used Cas9 from another bacteria, which they discovered “typically achieves 20-100 fold knockdown of [tuberculosis] gene expression.”91

Scientists in China have demonstrated another way to use CRISPR-Cas9 to prevent tuberculosis: editing tuberculosis resistance genes into an animal’s genome.92 The researchers used a

83. Koo & Kim, supra note 8, at 40.
84. See id.
85. Id.
86. Id.
87. Id.
89. Rock et al., supra note 88, at 2-3.
90. Id.
91. Id.
variant of CRISPR-Cas9 called CRISPR-Cas9n to insert a tuberculosis-resistant gene into a cow’s reproductive cell. That cell was then combined with a regular cow egg, forming a fetus that was nurtured in a lab before it was inserted into a cow that then had a regular pregnancy. When the genetically altered cows were later infected with tuberculosis, they showed a greater resistance to it than animals that had an unedited genome. This is an example of using CRISPR-Cas9 germline editing to achieve antibiotic effects.

3. Editing Somatic Cells

Researchers have conducted numerous studies testing CRISPR-Cas9 systems designed to edit genetic diseases out of human cells. Since CRISPR-Cas9 does not naturally occur in human cells, the gRNA and Cas9 either need to be delivered to the cells directly, or DNA coding for them needs to be inserted into the DNA of the cells so that the cells themselves produce the gRNA and the Cas9. Delivering the gRNA/Cas9 complex directly to the cells has many advantages, because then the cells’ defenses destroy the complex within 24 hours, which helps to limit off-target effects. However, this delivery method has only limited success (because not all cells obtain the Cas9/gRNA complex), so viral delivery is widely considered to be the superior method.

Scientists at the University of California, Berkeley, announced in 2017 that they had successfully used CRISPR-Cas9 to repair the mutation that causes muscular dystrophy in mice. The scientists injected mice that had muscular dystrophy with a CRISPR-Cas9 variant called CRISPR-Gold, a new CRISPR delivery mechanism.

---

93. Id.
94. Id.
95. Id.
97. Koo & Kim, supra note 8, at 40.
98. Id.
99. Id. The longer the complex is active in the cell, the greater the chances that it could create an off-target effect. See id.
100. Id.
that they had designed. The benefit of the CRISPR-Gold delivery mechanism is that it effectively transports the Cas9/gRNA complex into the cell intact, vitiating the need for a viral delivery mechanism. Researchers found that the CRISPR-Gold treatment "led to an 18-times-higher correction rate and a two-fold increase in a strength and agility test [in treated mice when] compared to control groups."

4. Editing Germline Cells

CRISPR-Cas9 could also be used to edit germline cells. The process works in a largely similar manner to edits made to somatic cells. The CRISPR-Cas9 complex is injected into the sperm or egg cells, or into the embryo very shortly after fertilization. Because the injection occurs so early in the life of the organism, the hope is that the corrected DNA will spread to most or all of the cells as the newly fertilized egg begins to divide. This treatment method can sometimes be ineffective due to "mosaicism," when the DNA edits are present in some of the cells, but not others. Researchers studying mice have found two to one hundred percent of cells in germline edited mice expressed the target sequence of DNA, rather than the corrected sequence that the scientists were trying to insert. Editing germline cells also leads to the possibility that edited DNA could be passed on to the next generation. If edited DNA is expressed in cells that manufacture sperm or eggs, then the genetic edits will be passed on to future generations.
In a study similar to the one conducted by the Berkeley muscular
dystrophy researchers, scientists at the University of Texas used
CRISPR-Cas9 to cure muscular dystrophy in mice.113 These re-
searchers, however, injected newly fertilized mouse eggs that had
the muscular dystrophy genes with the CRISPR-Cas9 system.114
While they did see a great deal of mosaicism in the adult mice, they
noted that the mice actually displayed stronger muscles than would
be expected based solely on gene expression.115 They surmised that
having even some properly working cells was an important treat-
ment outcome, because those properly functioning cells could have
a disproportionate positive impact on the mice.116

II. LEGAL LANDSCAPE

The American patent system is designed to encourage intellectu-
al inquiry by protecting ideas and inventions.117 Indeed, Congress
has granted patent protection to “[w]hoever invents or discovers any
new and useful process, machine, manufacture, or composition of
matter, or any new and useful improvement thereof,” subject only
to certain “conditions and requirements.”118 This Part will detail sev-
eral of those requirements, focusing primarily on what is required
for an invention to be patent-eligible subject matter.

A. General Requirements for Patentability

Section 101 of the Patent Act mandates that in order to qualify for
patent protection, the invention first needs to be patent-eligible sub-
ject matter—something for which a patent is even allowed to issue
(generally a physical object or a process).119 However, patents will
not issue for inventions that merely describe laws of nature.120 The

113. Chengzu Long et al., Prevention of Muscular Dystrophy in Mice by CRISPR/Cas9-
Mediated Editing of Germline DNA, 345 SCIENCE 1184, 1184 (2014).
114. Id. at 1184-85.
115. Id. at 1185-87.
116. Id.
117. See U.S. Const. art. I, § 8, cl. 8; Nuno Pires de Carvalho, The Primary Function of
119. See id.
Supreme Court articulated this rule in *Mayo Collaborative Services v. Prometheus Laboratories, Inc.*, where it held that “[i]f a law of nature is not patentable, then neither is a process reciting a law of nature, unless that process has additional features that provide practical assurance that the process is more than a drafting effort designed to monopolize the law of nature itself.”121 However, because “all inventions at some level embody, use, reflect, rest upon, or apply laws of nature,”122 the Court cautioned that “an application of a law of nature ... to a known structure or process may well be deserving of patent protection.”123

In *Alice Corp. v. CLS Bank International*, the Court explained that a two-step process should be used to determine whether a patent improperly embodies a law of nature.124 First, a court has to decide if the patent contains an abstract idea.125 Next, it must determine whether the patent contains a sufficient “inventive concept” beyond a mere instruction to apply the rule of nature.126 If the patent contains a sufficient inventive concept, and does not merely describe situations in which the law of nature should be applied, then patent protection is appropriate.127

Assuming that a patent application covers appropriate subject matter, it must still meet several other requirements for patentability.128 In order to be patentable, an invention must be useful,129 novel,130 non-obvious,131 and properly disclosed.132

---

121. *Id.* at 77.
122. *Id.* at 71.
123. *Id.* (quoting *Diamond v. Diehr*, 450 U.S. 175, 187 (1981)).
125. *Id.*
126. *Id.*
127. *Id.*
129. *Id.* § 101.
130. *Id.*
B. The America Invents Act Regime

The Leahy-Smith America Invents Act (AIA) adds some additional conditions for researchers to meet in order for their invention to qualify as patent-eligible subject matter. The AIA prevents patents from “issu[ing] on a claim directed to or encompassing a human organism.”134 While the AIA is meant to limit patent protection for certain types of research (and, indeed, seems designed to prevent that research altogether), it is not meant to prevent patents for all inventions that could be consumed or used by humans.135 Indeed, the drafters of the AIA specifically noted that patents should be allowed to issue “on genes, stem cells, animals with human genes, and a host of non-biologic products used by humans.”136 This means that while pharmaceuticals, which at a minimum have a strong relationship with human organisms, are able to gain patent protection,137 human embryos are not.138

The AIA did not radically change U.S. Patent and Trademark Office (USPTO) policy on the patentability of human organisms.139 Indeed, in a letter to Congress describing pre-AIA USPTO policy, Director of the USPTO James Rogan said that the AIA was “fully consistent with USPTO’s policy on the non-patentability of human life-forms.”140 Director Rogan further elaborated on long-standing USPTO policy, saying:

The USPTO’s policy of rejecting patent application claims that encompass human life-forms, which the Weldon Amendment

---

134. Id.
137. E.g., U.S. Patent No. 5,108,993 (issued Apr. 28, 1992) (a patent on a popular anti-HIV drug not declared invalid under long-standing USPTO policy or the AIA).
elevates to an unequivocal congressional prohibition, applies regardless of the manner and mechanism used to bring a human organism into existence (e.g., somatic cell nuclear transfer, in vitro fertilization, parthenogenesis). If a patent examiner determines that a claim is directed to a human life-form at any stage of development, the claim is rejected as non-statutory subject matter and will not be issued in a patent as such.141

The policy codified in the AIA therefore was consistent with long-standing USPTO practice, and focused primarily on whole organisms, not on smaller components like stem cells or DNA.142

C. The Law as Applied to Human Biology

USPTO policy and the proscriptions of the AIA143 have not prevented patents from issuing on all technologies arguably targeted at human biology.144 While human fetuses are consistently not patentable,145 valid patents have issued on human DNA146 and human stem cells.147

1. Fetuses

An example of the application of the AIA policy can be found in Ex parte Kamrava.148 In that case, the Patent Trial and Appeal Board (PTAB) affirmed the rejection of a patent application for a catheter that included “an embryo in the distal portion.”149 The patent applicant argued that the catheter was patent-eligible because the patent application did not actually encompass an embryo, and the embryo did not qualify as a part of the human body because “the

141. Id.
142. Id. These, of course, may have other barriers to patentability, including other limits on patentable subject matter. See, e.g., Mayo Collaborative Servs. v. Prometheus Labs., Inc., 566 U.S. 66, 72-73 (2012).
143. See supra Part II.B.
145. See infra Part II.C.1.
146. See infra Part II.C.2.
147. See infra Part II.C.3.
149. Id. at 5.
embryo in the distal portion of the catheter is a non-naturally occurring combination ... which is the product of human ingenuity.”

The PTAB ruled against the inventor on both arguments. They interpreted the patent application literally, and reasoned that if the inventor had not meant to include the embryo in the patent, she would have worded her application differently. Additionally, the PTAB ruled that combining the human embryo with the catheter did not make it patent-eligible, because “[t]he fact that the claims cover patent-eligible subject matter ... in combination with patent-ineligible subject matter ... does not render the claims patent-eligible.” Thus, in order for an invention to be patent-eligible, no part of it may be directed at a whole human organism.

2. DNA

The Supreme Court has, however, allowed patents to issue on genetically modified human DNA. In Ass’n for Molecular Pathology v. Myriad Genetics, Inc., the Court held that while naturally occurring DNA is a product of nature and is not patentable, DNA that does not occur naturally is patentable. Myriad dealt with a company that had discovered the sequence of genes that are implicated in a patient’s risk of developing breast and ovarian cancer. They tried to obtain a patent on the typical DNA sequence found in those genes. If granted, the patent would have given them “the exclusive right to isolate [the relevant] genes,” a step necessary to determine a patient’s cancer risk. The Court reasoned that

150. Id.
151. Id.
152. Id. (“As noted by the Examiner, if Appellant had intended not to encompass an embryo, the claims could have recited that ‘the distal portion of the catheter is adapted to receive/hold an embryo.”).
153. Id. at 6.
154. See id.
156. Id.
157. Id. at 582-83.
158. Id. at 583-84.
159. Id. at 585. The property interest in the particular gene sequences would have therefore doubtless been incredibly lucrative for Myriad. See Matthew Herper, Company Will Raise $1 Billion to Create Blood Test to Detect Cancer, FORBES (Jan. 5, 2017, 4:59 PM), https://www.forbes.com/sites/matthewherper/2017/01/05/grail-which-aims-to-invent-blood-test-to-
because the DNA sequences were naturally occurring, Myriad could not obtain a patent on them.\textsuperscript{160}

The \textit{Myriad} Court did, however, allow Myriad to obtain a patent on synthetic DNA that Myriad scientists created in a lab.\textsuperscript{161} Normal DNA contains both introns (regions that do not code for proteins)\textsuperscript{162} and exons (regions that do code for proteins).\textsuperscript{163} Myriad developed complementary DNA (cDNA) that contained only exon (coding) segments.\textsuperscript{164} The Court ruled that even though cDNA is based on the naturally occurring DNA sequences, because exon-only DNA strands do not occur in nature, Myriad was allowed to patent the cDNA.\textsuperscript{165}

The Federal Circuit recently decided \textit{Ariosa Diagnostics, Inc. v. Sequenom, Inc.} on a very similar basis.\textsuperscript{166} In \textit{Sequenom}, a company had found a way to isolate cell-free fetal DNA (cffDNA) from maternal blood.\textsuperscript{167} When a woman is pregnant, a small amount of cffDNA from her baby is present in her bloodstream.\textsuperscript{168} The company designed a test that could use cffDNA to learn about the baby’s characteristics and to look for genetic abnormalities.\textsuperscript{169} To test the DNA effectively, the company employed widely used techniques for isolating and amplifying DNA.\textsuperscript{170} The court reasoned that Sequenom’s patent failed both prongs of the \textit{Alice} test; because cffDNA was “naturally occurring,” and “the method steps were well-understood, conventional and routine,” Sequenom’s process did not add a sufficient “inventive concept” that would warrant patentability.\textsuperscript{171}
3. Stem Cells

The USPTO has extended patent protection to human stem cells for the past thirty years. However, the federal government has at times been openly hostile to stem cell research: from 1996 to 2009, federal funding could not be used for “research that destroyed [or] created human embryos.” President Obama lifted this ban in 2009 with an executive order that allowed funding for research that used embryos, but only “if th[o]se embryos were created during in vitro fertilization for reproductive purposes but were no longer needed for such purposes.”

Although patents on embryonic stem cells are controversial and the subject of frequent litigation, the USPTO and the courts have consistently allowed patents on many stem cell technologies. Indeed, researchers have noted a recent increase in patent applications on stem cell technologies that have therapeutic applications. This is in stark contrast to the practice at the European Patent Office (EPO), which “regards patents on [stem cells] as illegal because they are patents on a human body or human body part, offend human dignity, or involve commercial or industrial uses of embryos.” However, the willingness in America to grant patents to some stem cell therapies suggests that the door may be open to patents on some CRISPR-Cas9-based therapies, as well.

172. Sonya Davey et al., Interfacing of Science, Medicine and Law: The Stem Cell Patent Controversy in the United States and the European Union, 3 FRONTIERS CELL & DEVELOPMENTAL BIOLOGY, art. 71, Nov. 2015, at 3; see also Xuejun H. Parsons et al., Patents on Technologies of Human Tissue and Organ Regeneration from Pluripotent Human Embryonic Stem Cells, 1 RECENT PATENTS ON REGENERATIVE MED. 142, 144-45 (2011).
173. Davey et al., supra note 172, at 3.
174. Id.
175. Parsons et al., supra note 172, at 143.
176. Id.
177. Id.
178. The EPO, by contrast, has been hostile to many claims for CRISPR patent protection. See Kelly Servick, Broad Institute Takes a Hit in European CRISPR Patent Struggle, SCIENCE (Jan. 18, 2018, 3:30 PM), http://www.sciencemag.org/news/2018/01/broad-institute-takes-hit-european-crispr-patent-struggle [https://perma.cc/KV22-6NP5].
D. Scholarly Perspectives on the Patentability of CRISPR-Cas9

Although no commentator has yet written on whether therapeutic applications of CRISPR-Cas9 are eligible for patent protection, scholars have written extensively about the patentability of the CRISPR-Cas9 technology in general. Opinion on CRISPR-Cas9’s patent eligibility has been decidedly mixed, with some commentators arguing that it should not be patent eligible, and others maintaining stridently that it should.

Attorney Benjamin Tuttle contends that in light of Myriad and Alice, CRISPR-Cas9 systems are not eligible for patent protection because they “share molecular and genetic structure and function [with] the naturally-occurring molecules from which they derive.” Because they fail the first prong of the Alice test, Tuttle argues that CRISPR-Cas9 patents are subject to the second prong, which they also fail. Tuttle admits that CRISPR-Cas9 systems used to modify non-bacterial DNA qualify as an “inventive concept,” but says that policy considerations, such as the need to promote innovation, should outweigh the value of protecting the invention.

On the other hand, patent attorney Deborah Ku asserts that CRISPR-Cas9 technologies are patent eligible, and would survive a challenge to § 101 of the Patent Act because they satisfy the Alice framework. Ku argues that the CRISPR-Cas9 system at issue in the dispute between the Broad Institute and the University of California is patentable in part because it “possesses characteristics that are markedly different from the naturally-occurring counterpart found in select bacteria.” Ku contends that Tuttle fails to consider

---

179. See supra notes 16-18 and accompanying text.
180. Compare, e.g., Benjamin C. Tuttle, The Failure to Preserve CRISPR-Cas9’s Patentability post Myriad and Alice, 98 J. PAT. & TRADEMARK OFF. SOC’Y 391, 392, 404-05 (2016) (arguing that CRISPR-Cas9 systems fail both steps of the Alice test and that policy concerns militate against patentability), with Deborah Ku, The Patentability of the CRISPR-Cas9 Genome Editing Tool, 16 CHI.-KENT J. INTELL. PROP. 408 (2017) (arguing that a patent on CRISPR-Cas9 should at least survive a § 101 challenge).
181. Tuttle, supra note 180, at 404.
182. Id. at 404-05.
183. Id. at 405.
185. Id. at 434.
that while individual components of the CRISPR-Cas9 system might be found in nature, “the claimed system as a whole is not.”

Even if a court finds that the CRISPR-Cas9 system is the same as what occurs in nature, and therefore fails the first prong of the *Alice* test, Ku argues that CRISPR-Cas9 should be patent eligible because it satisfies the second prong of the test. Ku says that the CRISPR-Cas9 system claimed in the Broad Institute and University of California patents embodies a sufficient inventive concept to satisfy the second prong of the test because “getting the naturally-found CRISPR system ... to work in [non-bacterial] cells required human intervention.” Thus, Ku argues, CRISPR-Cas9 systems should be patentable, at least as they are defined in the patents filed by the Broad Institute and the University of California.

Under the existing regulatory regime, the extent to which the therapeutic applications of CRISPR-Cas9 are patentable remains an open question. Inventors that attempt to patent DNA-based therapies face significant barriers to patentability, including whether their invention already occurs in nature and is therefore not patent-eligible subject matter, and whether they are so widely used that creating them required no inventive step. This is not to mention one of the largest barriers to patentability for CRISPR-Cas9 therapies: the AIA’s prohibition against patents “directed to or encompassing a human organism.”

**III. ARE CRISPR-CAS9 THERAPIES PATENTABLE?**

The extent to which patent law (particularly the AIA) allows patent protection to extend to therapeutic applications of CRISPR-Cas9 systems remains unclear. CRISPR-Cas9 therapies face several
hurdles to patentability: the applicant must demonstrate that the therapies (1) do not already occur in nature\textsuperscript{195} or (2) embody a sufficient inventive concept,\textsuperscript{196} and (3) are not “directed to or encompassing a human organism.”\textsuperscript{197} As discussed below, some therapeutic applications of CRISPR-Cas9 will clear these hurdles, whereas others will not. This Part argues that therapeutic applications of CRISPR-Cas9 analogous to existing disease treatments (namely, CRISPR-Cas9 treatments of viral and bacterial infections) should be granted patent protection, whereas applications that do not have an existing therapeutic analog (somatic and germline cell editing) should not.

A. Where Patent Protection Will Apply

CRISPR-Cas9 therapies used to treat viral and bacterial infections should be granted patent protection. These therapies do not already occur in nature,\textsuperscript{198} they are not yet so broadly used that they do not require an inventive concept,\textsuperscript{199} and they are not “directed to or encompassing a human organism”\textsuperscript{200} in violation of the AIA.\textsuperscript{201}

1. Treating Viral Infections

The anti-viral applications of CRISPR-Cas9 should be granted patent protection. As explained below, anti-viral applications of CRISPR-Cas9 clear all three of the hurdles to patentability for CRISPR-Cas9 therapies. These applications do not occur in nature, the techniques for delivering the treatment are not widely used,

\textsuperscript{195} Myriad, 569 U.S. at 591.
\textsuperscript{196} Alice, 134 S. Ct. at 2357; Ariosa Diagnostics, Inc. v. Sequenom, Inc., 788 F.3d 1371, 1379-80 (Fed. Cir. 2015).
\textsuperscript{197} Leahy-Smith America Invents Act (AIA) § 33(a). There are, of course, other requirements for patentability, such as adequate disclosure, but these are not unique or particularly challenging in the CRISPR-Cas9 context, so they are not addressed here. See, e.g., 35 U.S.C. § 112 (2012).
\textsuperscript{198} See infra notes 202-11 and accompanying text.
\textsuperscript{199} See infra notes 212-18 and accompanying text.
\textsuperscript{200} Leahy-Smith America Invents Act (AIA) § 33(a).
\textsuperscript{201} See infra notes 219-24 and accompanying text.
and the treatment is not “directed to or encompassing a human organism” within the meaning of the AIA.\textsuperscript{202}

As a threshold matter, humans do not naturally use CRISPR-Cas9 to combat viral infection.\textsuperscript{203} As the Supreme Court’s decision in \textit{Myriad} shows, demonstrating that an invention does not occur in nature is a low bar.\textsuperscript{204} A patent applicant need only show that the invention does not specifically occur in nature.\textsuperscript{205} In \textit{Myriad}, even though the order of the nucleotides in the cDNA came from naturally occurring DNA, Myriad successfully patented the cDNA sequence because it excluded the introns that were present in the natural DNA sequence.\textsuperscript{206}

Although some organisms use CRISPR-Cas9 systems as part of an immune response in nature, they are not naturally part of the human immune system.\textsuperscript{207} CRISPR-Cas9 evolved as an immune response in bacteria.\textsuperscript{208} Researchers have never recorded CRISPR-Cas9 as a natural component of the human immune system.\textsuperscript{209} Therefore, under the \textit{Myriad} standard,\textsuperscript{210} inventors should still be allowed to patent CRISPR-Cas9 systems used to treat viral infections, because the CRISPR-Cas9 system is not a natural part of the \textit{human} immune response.\textsuperscript{211}

Even assuming that a court finds that CRISPR-Cas9-based therapies are naturally occurring, the techniques used to deliver CRISPR-Cas9 systems into cells are not yet widely used,\textsuperscript{212} and thus require a sufficient inventive concept that satisfies the second prong of the \textit{Alice} analysis.\textsuperscript{213} Because human cells do not naturally contain Cas9 proteins, researchers cannot merely inject gRNA into virus-infected cells and expect the gRNA to kill the viruses.\textsuperscript{214}

\begin{flushright}
\textsuperscript{202} Leahy-Smith America Invents Act (AIA) § 33(a); see infra notes 219-24 and accompanying text.
\textsuperscript{203} Sternberg \& Doudna, supra note 9, at 568.
\textsuperscript{204} See Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576, 595 (2013).
\textsuperscript{205} See id.
\textsuperscript{206} Id.
\textsuperscript{207} Sternberg \& Doudna, supra note 9, at 568.
\textsuperscript{208} Id.
\textsuperscript{209} See id.
\textsuperscript{210} 569 U.S. at 595.
\textsuperscript{211} See Sternberg \& Doudna, supra note 9, at 568.
\textsuperscript{212} See Israel, supra note 101.
\textsuperscript{213} See Alice Corp. Pty. Ltd. v. CLS Bank Int’l, 134 S. Ct. 2347, 2357 (2014).
\textsuperscript{214} See Israel, supra note 101.
\end{flushright}
Instead, researchers must find a way to get the entire Cas9/gRNA complex into the cell.\textsuperscript{215} However, this is incredibly difficult to do.\textsuperscript{216} When the Berkeley researchers announced that they had found a way to use gold particles to transport a Cas9/gRNA complex into the cells of mice suffering from muscular dystrophy, it was groundbreaking news.\textsuperscript{217} Because (1) this technique was developed relatively recently, (2) researchers have only published one paper describing it,\textsuperscript{218} and (3) its efficacy has not been demonstrated for other treatments, the delivery techniques for CRISPR-Cas9 anti-viral treatments require an inventive concept that satisfies the second prong of the Alice analysis.

Finally, the anti-viral uses of CRISPR-Cas9 systems are not “directed to or encompassing a human organism”\textsuperscript{219} within the meaning of the AIA. Neither the long-standing USPTO policy against issuing patents encompassing human beings, nor the AIA, have prevented patents from issuing on antiviral drugs.\textsuperscript{220} It is important to note that a CRISPR-Cas9 treatment for a viral infection is patentable only to the extent that it targets the virus’s DNA, not the patient’s.\textsuperscript{221} The CRISPR-Cas9 anti-viral treatments that have been proposed edit out specific portions of the viral DNA, leaving the patient’s DNA unaltered and thus avoiding this problem.\textsuperscript{222} Because CRISPR-Cas9 treatments do not alter the human genome in any way,\textsuperscript{223} they are no different—with the exception of their incredible effectiveness—than other anti-viral

\textsuperscript{215} Id.
\textsuperscript{216} See id.
\textsuperscript{217} See id.
\textsuperscript{218} At the time this Note was written. See id.
\textsuperscript{220} See, e.g., U.S. Patent No. 5,108,993 (issued Apr. 28, 1992) (a patent on a popular anti-HIV drug not declared invalid under long-standing USPTO policy or the AIA).
\textsuperscript{221} See Kaminski et al., supra note 80, at 10 (“[W]e developed CRISPR/Cas9 techniques that eradicated integrated copies of HIV-1 [DNA] from human ... cells, inhibited HIV-1 infection in ... human ... cells, and suppressed viral replication \textit{ex vivo} in ... cells of HIV-1+ patients.”).
\textsuperscript{222} See id.
\textsuperscript{223} Id.
drugs that have been granted patent protection. They should therefore not be treated any differently on their patent applications.

2. Treating Bacterial Infections

Like the anti-viral applications of CRISPR-Cas9, the anti-bacterial applications should also be granted patent protection. The analysis here is largely similar to the anti-viral application analysis. Although CRISPR-Cas9 systems naturally occur as an immune response in bacteria, the response is geared towards fighting viral infections, and is not directed against the bacteria itself. Therefore, anti-bacterial applications of CRISPR-Cas9 do not occur in nature. The techniques for delivering anti-bacterial CRISPR-Cas9 treatments are also not widely used, because they were only recently developed. Although some bacteria already contain Cas9 proteins that could be paired with an inserted gRNA, it is more useful to insert an entire Cas9/gRNA complex, a technique that has not yet been tested in humans. Finally, because the CRISPR-Cas9 treatments destroy bacterial DNA, and no human DNA, the treatments do not run afoul of the AIA. Anti-bacterial applications of CRISPR-Cas9 should therefore be patentable.

B. Where Patent Protection Will Not Apply

On the other hand, CRISPR-Cas9 therapies used to edit somatic and germline cells should not be granted patent protection. While these therapies satisfy both prongs of the Alice analysis because they do not already occur in nature and do require an inventive
concept, they are “directed to or encompassing a human organism” in violation of the AIA.

1. Editing Somatic Cells

Patent protection should not be granted to CRISPR-Cas9 systems designed to edit somatic cells. These systems fail to clear the final hurdle to patentability. While somatic cell editing of this kind does not occur in nature and does use techniques that are wide-spread, it is still not patentable because it is “directed to or encompassing a human organism.”

CRISPR-Cas9-mediated somatic cell editing does not occur in nature under the Myriad standard (or, for that matter, under any other rational standard). As discussed above in Part I.B.3, CRISPR-Cas9 evolved as an immune response in bacteria and is only present in bacteria. Although CRISPR-Cas9 does naturally occur in bacteria, editing somatic cells in humans is not its natural use. Inventors would have a stronger patent claim to this use than the inventors in Myriad had to the cDNA. There, the researchers were only removing certain portions of the naturally occurring DNA. Here, inventors are completely altering what the naturally-occurring phenomenon is used for.

Somatic-cell editing using CRISPR-Cas9 also does not employ widely-used techniques, and thus requires an inventive leap that satisfies the second prong of the Alice test. Because human cells do not have Cas9 proteins already in them, researchers cannot merely inject gRNA into cells that they want to edit and expect that the edits will actually occur. Instead, researchers must find a way to get the entire Cas9/gRNA complex into the cell. However, as

232. See infra notes 240-46, 254-56 and accompanying text.
234. See infra notes 240-43, 253-57 and accompanying text.
235. Leahy-Smith America Invents Act (AIA) § 33(a).
236. See supra Part I.B.3.
237. See Israel, supra note 101.
239. Id.
241. See Koo & Kim, supra note 8, at 40.
242. See id.
discussed above, this is incredibly difficult to do.\textsuperscript{243} The muscular dystrophy researchers who discovered CRISPR-Gold just published their discovery, and the technique has yet to be attempted in humans.\textsuperscript{244} Because this technique was developed relatively recently, and because researchers have only published one paper describing it, the delivery techniques for CRISPR-Cas9 somatic cell editing treatments are certainly not wide-spread, and require an inventive concept to apply.\textsuperscript{245} Therefore, CRISPR-Cas9 treatments that edit somatic cells clear both prongs of the \textit{Alice} test.\textsuperscript{246}

The stumbling block for researchers seeking to patent somatic cell-editing CRISPR-Cas9 systems is the provision of the AIA that dictates that no patent may be issued for a technology that is “directed to or encompassing a human organism.”\textsuperscript{247} By their very nature, CRISPR-Cas9 systems used to edit somatic cell DNA are designed to alter a human organism.\textsuperscript{248} Indeed, the invention of CRISPR-Gold as a delivery mechanism, which solves the problem of how to efficiently deliver the Cas9/gRNA complex into somatic cells,\textsuperscript{249} only complicates the AIA issue. Whereas before scientists would have injected the Cas9/gRNA complex directly into the cells they wished to affect, now they simply have to inject the solution containing the Cas9/gRNA complexes into the body of the patient, potentially impacting any cell containing the target DNA.\textsuperscript{250} An invention that has the potential to fundamentally alter the DNA in every cell in the body is clearly “directed to ... a human organism,”\textsuperscript{251} and should not receive patent protection under the AIA.

\subsection*{2. Editing Germline Cells}

CRISPR-Cas9 systems designed to edit germline cells should also not be granted patent protection. The analysis here is very similar

\begin{itemize}
\item \textsuperscript{243} See Israel, supra note 101.
\item \textsuperscript{244} Id.
\item \textsuperscript{245} See id.
\item \textsuperscript{246} Alice Corp. Pty. Ltd. v. CLS Bank Int’l, 134 S. Ct. 2347, 2355 (2014).
\item \textsuperscript{247} Leahy-Smith America Invents Act (AIA), Pub. L. No. 112-29, § 33(a), 125 Stat. 340 (2011).
\item \textsuperscript{248} Israel, supra note 101.
\item \textsuperscript{249} Id.
\item \textsuperscript{250} See id.
\item \textsuperscript{251} Leahy-Smith America Invents Act (AIA) § 33(a).
\end{itemize}
to the somatic cell system analysis above: systems designed to edit germline cells clear the first two hurdles to patentability, but stumble upon the third. CRISPR-Cas9 does not naturally edit germline cells in nature. 252 It does not even naturally occur in humans, and in the bacteria where it does naturally appear, it is used solely for the purpose of destroying viral DNA. 253 Germline editing systems therefore exceed the Myriad standard. 254 Germline editing using CRISPR-Cas9 also does not use techniques that are widely employed, and thus require an inventive concept. 255 There is (as of yet) no wide-spread genetic editing of any kind of human germline cells. 256

The argument is even stronger for CRISPR-Cas9-mediated editing of germline cells than it is for somatic cells that the technique is “directed to or encompassing a human organism.” 257 The benefit of germline editing (from a research and treatment perspective) is that if scientists can overcome issues with mosaicism, the altered DNA will be expressed in every cell of the adult body. 258 An invention designed to fundamentally alter the DNA in every cell in the body is clearly “directed to ... a human organism.” 259 The altered DNA also has the potential to be passed on to the offspring of edited individuals, ensuring that the offspring will have edited DNA fully incorporated into their genome. 260 Moreover, serious ethical concerns will likely prevent the USPTO from issuing patents on any technology that could so fundamentally alter a person’s genetic code. 261 For these reasons, CRISPR-Cas9 systems designed to edit germline cells should also be unpatentable.

252. Sternberg & Doudna, supra note 9, at 568.
253. Id.
255. See, e.g., Rana et al., supra note 13 (noting the only known CRISPR-Cas9 therapy currently being used in humans is a treatment for cancer patients).
256. See Neergaard, supra note 14.
258. Koo & Kim, supra note 8, at 40.
259. Leahy-Smith America Invents Act (AIA) § 33(a).
260. Koo & Kim, supra note 8, at 40.
261. See Letter from James Rogan, Dir., U.S. Patent & Trademark Office, to Ted Stevens, Chairman, Comm. on Appropriations, U.S. Senate, supra note 140.
IV. COUNTERARGUMENTS

This Part addresses counterarguments to the normative framework outlined in Part III. It considers and rejects arguments that CRISPR-Cas9 should not be patentable at all;262 that patents have been granted on some CRISPR-Cas9-based therapies, and therefore all therapies should be patentable;263 and that certain somatic cell editing should be patentable.264

A. CRISPR-Cas9 Should Not Be Patentable at All

As noted above, some scholars have argued that CRISPR-Cas9 should be considered unpatentable altogether.265 Benjamin Tuttle believes that Myriad and Alice foreclose patentability for all CRISPR-Cas9 systems, because they “share molecular and genetic structure and function to the naturally-occurring molecules from which they derive.”266 Tuttle argues that the systems thus fail the first prong of the Alice test, and are subject to the second prong, which he claims they also fail.267 Tuttle admits that CRISPR-Cas9 systems used to modify non-bacterial DNA may qualify as an “inventive concept,” but argues that policy considerations should outweigh the value of protecting the invention.268 In the context of the subset of CRISPR-Cas9 systems that could be used as therapies for human illness, Deborah Ku may actually support Tuttle.269 She writes that patent protection applies when “the claimed CRISPR system is not used as an immune system, but as a genome editing tool. Hence its function is different [than it would be in nature].”270

Tuttle’s paper was written in the context of the patent dispute between The Broad Institute and the University of California, and

262. Infra Part IV.A.
263. Infra Part IV.B.
264. Infra Part IV.C.
265. Tuttle, supra note 180, at 392; supra notes 181-83 and accompanying text.
266. Tuttle, supra note 180, at 404.
267. Id. at 404-05.
268. Id. at 405.
269. See Ku, supra note 180, at 435.
270. Id.
does not directly deal with therapeutic applications of CRISPR-Cas9.271 Taken in the context of therapeutic applications, however, his arguments about the patentability of CRISPR-Cas9 carry significantly less weight. His arguments fail to account for the magnitude of the inventive leap when a genetic system used as part of an immune response in bacteria is repurposed as a medical treatment in humans.272

As Ku wrote in her paper, even assuming that CRISPR-Cas9 systems fail the first prong of the Alice test, they do not fail the second.273 The human intervention required to transform a bacterial immune response into a genetic-editing technology that can be used in human cells is an inventive leap large enough to satisfy the second prong of the Alice test.274 This is a massive step forward that reflects the culmination of the policy goals that Tuttle expresses,275 and far outweighs any reasons not to grant patent protection to CRISPR-Cas9 therapies in some instances.

B. Patents Have Issued on Some CRISPR-Cas9-Based Therapies

In contrast, those arguing in favor of granting patents on all CRISPR-Cas9-based therapies might observe that patents already have issued on CRISPR-Cas9 systems used to edit human immune cells,276 and patents should therefore be issued on all CRISPR-based therapies. However, this position fails to account for the fact that while patents are given a presumption of validity,277 “the ultimate question of patent validity is one of law,” to be determined by a court.278 Until a court has determined the validity of these

271. Id. at 436; Tuttle, supra note 180, at 404-05.
272. See Koo & Kim, supra note 8, at 40.
275. Tuttle, supra note 180, at 405.
patents, there is no reason to believe that patents on CRISPR-Cas9 therapies are per se valid.

C. Some Somatic Cell Editing Should Be Patentable

In a similar vein, CRISPR-Cas9 therapies that edit certain somatic cells arguably should be patentable. For example, CRISPR-Cas9 therapies could be used to knock out the genes that cause unrestricted growth in tumor cells.279 Such unrestricted growth is not normally present in the human genome,280—the argument goes—so destroying the genes that cause it using CRISPR-Cas9 is a treatment that is not “directed to or encompassing a human organism.”281

What this argument fails to account for is that tumor cells are created when human DNA is mutated so that the factors that normally restrict cell growth are no longer active.282 The cancer cells still have human DNA, and even if that particular expression of DNA is not the default in humans, it does still naturally occur in them.283 Any attempt to edit out the mutation is thus an attempt to edit human DNA in a live patient, and is therefore “directed to ... a human organism.”284

CONCLUSION

In his short story, Boyle paints a dark and concerning picture of a CRISPR-mediated future, made all the more worrisome because, as discussed above,285 many of the steps that he describes have already been taken:

When the CRISPR technology first came to light, governments and scientists everywhere assured the public that it would be

280. Id.
282. Lobo, supra note 279.
283. Id.
284. Leahy-Smith America Invents Act (AIA) § 33(a).
285. See supra Part I.B.
employed only selectively, to fight disease and to rectify congenital deformities, editing out the mutated BRCA1 gene that predisposes women to breast cancer, for instance, or eliminating the ability of the Anopheles mosquito to carry the parasite that transmits malaria. Who could argue with that? Genome-editing kits (“Knock Out Any Gene!”) were sold to home hobbyists, who could create their own anomalous forms of yeast and bacteria in their kitchens, and it was revolutionary—and, beyond that, fun. Fun to tinker. Fun to create.... The Chinese were the first to renounce any sort of regulatory control and upgrade the human genome, and, as if they weren’t brilliant enough already, they became still more brilliant as the first edited children began to appear, and of course we had to keep up.\textsuperscript{286}

Fortunately, safeguards in intellectual property laws will likely mean that CRISPR-Cas9 therapies are only patentable under the Myriad standard and the AIA when they do not lead to upgrading the human genome.\textsuperscript{287} DNA in somatic or germline cells is incorporated into the body, and, in the case of the germline cells (or an organ donor who gives an organ containing DNA edited by CRISPR), could even be passed on to another person.\textsuperscript{288} CRISPR-Cas9 systems in somatic or germline cells should not be patentable under the AIA, because they are “directed to ... a human organism.”\textsuperscript{289} However, CRISPR-centered treatments for viral and bacterial infections \textit{should} be patentable.\textsuperscript{290} Like pharmaceuticals, they should not lose their patent protection simply because they entered the human body.\textsuperscript{291} Because they do not occur in nature and represent an inventive leap, antiviral and antibacterial CRISPR-Cas9 treatments satisfy the Myriad and Alice standards.\textsuperscript{292} Likewise, the genetic editing techniques used to treat viral and bacterial infections will not run afoul of the AIA, because, like current pharmaceuticals, they are directed at foreign organisms that inhabit humans, and not the “human organism” itself.\textsuperscript{293} This is no small

\begin{footnotesize}
\textsuperscript{286} Boyle, supra note 1.
\textsuperscript{287} See supra Part III.A.
\textsuperscript{288} See supra Parts I.B.3, I.B.4.
\textsuperscript{289} Leahy-Smith America Invents Act (AIA) § 33(a); see also supra Part III.B.
\textsuperscript{290} See supra Part III.A.
\textsuperscript{291} See supra Part II.A.
\textsuperscript{292} See supra Part III.A.
\textsuperscript{293} See supra Part II.
\end{footnotesize}
step forward. Currently, there are no cures for viral infections, including those that are highly lethal (such as HIV/AIDs), and those that are incredibly common (the flu). Additionally, the rapid evolution of bacteria means that antibiotic-resistant strands of highly dangerous illnesses like tuberculosis will soon be entirely unsusceptible to traditionally effective antibiotics, requiring a new kind of treatment entirely.

The patent system as it exists now will help to ensure that some of the therapeutic applications of CRISPR-Cas9 receive protection, while others, too clearly “directed to ... a human organism” will remain unprotected. This outcome should help prevent some of the ethical concerns that Boyle highlights about CRISPR-Cas9 therapies from becoming a reality.

Noah C. Chauvin*

---

297. See Boyle, supra note 1.
* J.D. Candidate, 2019, William & Mary Law School; B.A., Biology and English Literature, 2016, State University of New York College at Geneseo. Thank you to Matthew Rosendahl for shepherding this Note through many drafts, Samuel Chauvin for verifying the scientific information, and the entire Law Review Notes team for helpful input and edits. Thank you also to my family and friends, who support me in all my endeavors.